You are viewing the site in preview mode

Skip to main content

Advertisement

Table 4 Analysis of distribution of pathogens during study period

From: Effects of long-term use of macrolides in patients with non-cystic fibrosis bronchiectasis: a meta-analysis of randomized controlled trials

Pathogens No. of studies Events/Total Effect size Heterogeneity
  Macrolide Control OR(95%CI) P I 2 (%) P
Eradication a       
Anyb 3 39/104 28/99 1.76(0.91,3.41) 0.09 31 0.23
H. i 6 44/219 23/208 2.06(1.19,3.56) 0.01* 27 0.23
P. a 4 20/161 15/154 1.32(0.63,2.77) 0.46 0 0.63
S. a 3 5/106 7/102 0.69(0.22,2.12) 0.51 0 0.45
S. p 2 4/63 7/62 0.50(0.13,1.94) 0.32 38 0.20
M. c 3 13/130 4/122 2.95(0.99,8.87) 0.05* 38 0.20
Newly appearance
Anyb 4 28/163 36/157 0.68(0.37,1.23) 0.20 0 0.51
H. i 4 14/163 17/157 0.79(0.38,1.63) 0.52 61 0.05
P. a 2 6/105 6/103 0.98(0.32,3.02) 0.97 35 0.21
S. a 2 3/87 1/82 1.9(0.34,10.61) 0.47 47 0.17
S. \( {\mathrm{p}}_{=}^{\mathrm{d}} \) 1 2/46 0/45 5.11(0.24,109.51) 0.30 - -
M. c 2 0/87 6/82 0.12(0.01,1.04) 0.05* 0 0.97
  1. Abbreviations: H. i, Haemophilus influenzae; P. a, Pseudomonas aerugiosa; S. a, Staphylococcus aureus; S. p, Streptococcus pneumoniae; M. c, Moraxella catarrhalis; OR (95%CI), Odds Ratio (95% confidential interval). aPathogens reported eradicated during study period; bany of the pathogens reported in the included studies; dThere was only one study reported S.p resistance, so Heterogeneity of this subgroup could not analysis; *It was suggestive of statistical significance.